Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Compliance, Chronic Pain
Interventions: acetazolamide, Quinine, Riboflavin; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episodes
Interventions: KindVR Aqua Program; Device
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 8 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder, Buprenorphine
Interventions: Brixadi (Injectable Buprenorphine), Sublocade; Drug
Lead sponsor: Lifespan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cranston, Rhode Island

Conditions: Alcoholism
Interventions: naltrexone; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Covid19
Interventions: Metformin, Naltrexone; Drug
Lead sponsor: AgelessRx; Industry
Eligibility: 30 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine, Buprenorphine and Naloxone, Hydromorphone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 1998
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Self-Injurious Behavior, Mental Retardation
Interventions: Naltrexone hydrochloride, Transcutaneous sensory nerve stimulation; Drug · Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Morganton, North Carolina

Conditions: Neonatal Abstinence Syndrome
Interventions: buprenorphine, Oral morphine solution; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypogonadotropic Hypogonadism, Low Testosterone
Interventions: Naloxone; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal patch, Placebo transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 48
States / cities: Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more

Conditions: Opioid Safety, Prescription Opioid Misuse, Chronic Pain
Interventions: ISOP Intervention with the Nurse Care Manager; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions: Naltrexone, Sugar Pill; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative
Interventions: Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine; Drug · Other
Lead sponsor: Neumentum, Inc.; Other
Eligibility: 18 Years to 64 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more

Conditions: Video Assisted Thoracoscopic Surgery, Pain, Postoperative, Pain, Acute
Interventions: US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion), US Guided Paravertebral Catheter (0.2% ropivicaine bolus), Thoracic Epidural (0.125% bupivicaine/hydromorphone); Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Adults
Interventions: Naltrexone and 2-butanol, 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form); Drug
Lead sponsor: Xhale Assurance; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Inflammation
Interventions: Morphine Sulfate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Opioid Tolerance
Interventions: Low Dose Naloxone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 1 Day to 18 Years
Enrollment: 128 participants
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Malignant Pleural Effusion, Pleural Effusion
Interventions: Large bore chest drain + NSAID based analgesic regimen, Small bore chest drain + NSAID based analgesic regimen, Large bore chest drain + opiate based analgesic regimen, Small bore chest drain + opiate based analgesic regimen; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions: Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 47 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Pain
Interventions: Not listed
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain
Interventions: Oxymorphone; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Cancer
Interventions: Oxycodone/acetaminophen 5/325 mg, Proteus digital medicine program; Drug · Device
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Decatur, Illinois • Urbana, Illinois • Billings, Montana + 2 more

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 19 Years to 57 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1997
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

Injectable Buprenorphine in Prison: A Preference Trial

Naltrexone for Early Problem Drinkers

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

Self-Injury: Diagnosis and Treatment

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

Opioid Antagonism in Hypogonadotropic Hypogonadism

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

A Patient-Centered Intervention to Improve Opioid Safety

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.

An Adherence Tool to Manage Narcotic -Addicted HIV Patients

Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans

Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients

The First Therapeutic Intervention in Malignant Pleural Effusion Trial

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20

Brain Response to Pain Control in People With Chronic Pain

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

S1916 Digital Medicine Program for Pain Control in Cancer Patients

Trial of Buprenorphine/Naloxone for Opiate Dependence - 2